Drug Insights

Harnessing Synapse for Diazepam Information: Strategies and Tips

11 February 2024
2 min read

The pharmacological agent Diazepam, a preeminent GABAA receptor agonist that was granted approval on November 15, 1963, by Waylis, is an efficacious medication used to mitigate a range of conditions, including muscle spasticity, alcohol abstinence, anxiety disorders, and epilepsy. The intricate chemical composition of this pharmacological agent is 7-chloro-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one. The multifaceted mechanism by which Diazepam operates is by potentiating the effects of gamma-Aminobutyric acid (GABA), an inhibitory neurotransmitter, thereby producing a tranquilizing effect on the body. The pervasiveness of Diazepam within the fields of psychiatry and neurology is incontrovertible, and its usage has become indispensable in the management of a broad spectrum of medical conditions. Click on the image below to begin the exploration journey of Diazepam through the Synapse database!

图形用户界面, 应用程序, 电子邮件

描述已自动生成

You can search for the latest pharmaceutical information such as drugs, targets, patents, transactions, clinical results, etc. through the Synapse database. Come and experience it!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

EMA Accepts Submission for Linvoseltamab as Therapy for Recurrent/Resistant Multiple Myeloma
Latest Hotspot
3 min read
EMA Accepts Submission for Linvoseltamab as Therapy for Recurrent/Resistant Multiple Myeloma
11 February 2024
Regeneron Pharmaceuticals, Inc. revealed that the European Medicines Agency is reviewing their Marketing Authorization Application for the therapy, linvoseltamab.
Read →
Effortless Searching: How to Find Methylphenidate on Synapse
Drug Insights
2 min read
Effortless Searching: How to Find Methylphenidate on Synapse
11 February 2024
Methylphenidate hydrochloride is a leading CNS stimulant, first approved by the US on December 5, 1955, and developed by Novartis. It effectively treats narcolepsy, ADD, and ADHD.
Read →
4DMT's Study Shows Promising Outcomes for Eye Injection 4D-150 in Treating Wet Age-Related Macular Degeneration
Latest Hotspot
3 min read
4DMT's Study Shows Promising Outcomes for Eye Injection 4D-150 in Treating Wet Age-Related Macular Degeneration
11 February 2024
4DMT Unveils Encouraging Early Results of the Phase 2 PRISM Study for the Eye Injection 4D-150, Indicating Good Safety and Efficacy in Treating Wet Age-Related Macular Degeneration.
Read →
Making the Most Out of Synapse: Searching for Carvedilol
Drug Insights
2 min read
Making the Most Out of Synapse: Searching for Carvedilol
11 February 2024
Carvedilol, sold under the trade name Coreg, is a medication that was first approved in Belgium in 1990.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.